眼附属器淋巴瘤的治疗:美国眼科学会报告
该报告由美国眼科学会基于截至2017年3月的文献检索,纳入27项研究共2009例患者,评估眼附属器淋巴瘤(OAL)现有治疗的疗效与并发症。MALT淋巴瘤放疗局部控制率平均95.9%,5年与10年无病生存率分别为86.4%和78.7%;非MALT或多亚型淋巴瘤放疗局部控制率93.1%,5年与10年无病生存率分别为75.7%和71.0%。
要点
- MALT淋巴瘤放疗局部控制率平均95.9%,5年与10年无病生存率分别为86.4%和78.7%。
- 纳入研究中75%的病例为黏膜相关淋巴组织(MALT)结外边缘区淋巴瘤。
- 多西环素治疗MALT淋巴瘤(137例)完全缓解率4.4%至13%,完全与部分缓解合计26.7%至65%。
核心结论
- 对于MALT淋巴瘤,放疗的局部控制、无病生存和总生存均良好。
- 非MALT淋巴瘤放疗结果亦良好,但不如MALT淋巴瘤的治疗结果。
研究设计与样本
- 美国眼科学会报告,文献检索最后于2017年3月在PubMed和Cochrane Library数据库进行,纳入英文原创研究评估OAL治疗结局。
- 检索识别307条唯一引用,按本评估标准选出27项研究,共2009例患者。
- 治疗对象为年龄大于13岁的患者。
主要发现
- 27项研究共2009例患者,报告的病例中75%为黏膜相关淋巴组织(MALT)结外边缘区淋巴瘤。
- 25项研究报告了放疗联合或不联合化疗或手术的结果。
- MALT淋巴瘤放疗局部控制率平均95.9%;仅报告MALT淋巴瘤的研究(884例)5年和10年无病生存率分别为86.4%和78.7%,接受放疗患者5年和10年总生存率分别为93.8%和84.9%。
- 包含多组织学亚型或非MALT淋巴瘤的研究(988例)局部控制率93.1%,5年和10年无病生存率分别为75.7%和71.0%,5年和10年总生存率分别为78.9%和73.5%。
- 多西环素治疗MALT淋巴瘤的研究(137例)报告完全缓解率4.4%至13%,完全与部分缓解合计26.7%至65%,无病生存未报告,无进展生存为55%至60.9%。
关键数值与推荐
- MALT淋巴瘤放疗局部控制率平均95.9%。
- 仅MALT淋巴瘤研究(884例)5年和10年无病生存率分别为86.4%和78.7%,5年和10年总生存率分别为93.8%和84.9%。
- 多组织学亚型或非MALT淋巴瘤研究(988例)局部控制率93.1%,5年和10年无病生存率分别为75.7%和71.0%,5年和10年总生存率分别为78.9%和73.5%。
- 多西环素治疗MALT淋巴瘤(137例)完全缓解率4.4%至13%,完全与部分缓解合计26.7%至65%,无进展生存55%至60.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the literature to determine the efficacy of available treatments for ocular adnexal lymphoma (OAL) and to evaluate the outcomes and complications of treatments in patients older than 13 years. METHODS: A literature search was conducted last in March 2017 in the PubMed and Cochrane Library databases for English-language original research investigations that evaluated treatment outcomes for OAL. The searches identified 307 unique citations, and 27 studies were selected according to the criteria outlined for this assessment. RESULTS: The 27 studies reviewed comprised 2009 patients. Seventy-five percent of the cases reported were extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). Twenty-five studies reported results using radiotherapy with or without chemotherapy or surgery. The local control rate of MALT lymphomas with treatments involving radiotherapy averaged 95.9%. Distant and local relapses can occur, and in studies reporting only on MALT lymphomas (884 patients), the 5-year and 10-year disease-free survival rates were reported to be 86.4% and 78.7%, respectively. However, overall survival in patients receiving radiotherapy remained very good, with the 5-year and 10-year survival rates reported to be 93.8% and 84.9%, respectively. Studies that included data on multiple histologic subtypes of lymphoma or non-MALT lymphomas (988 patients) reported local control rates to be 93.1%; 5-year and 10-year disease-free survival rates to be 75.7% and 71.0%, respectively; and 5-year and 10-year overall survival rates to be 78.9% and 73.5%, respectively. Studies on the use of doxycycline for MALT lymphomas (137 patients) reported complete responses of between 4.4% and 13%. Complete and partial responses combined were between 26.7% and 65%. Disease-free survival was not reported for these 2 studies, although progression-free survival was reported to be between 55% and 60.9%. The most frequently reported complications of treatment were cataracts (12.1%) and dry eye (8.5%). CONCLUSIONS: For MALT lymphomas, local control, disease-free survival, and overall survival are good with radiation treatment. The results of treatment of non-MALT lymphomas using radiotherapy also were good, but they were not as favorable as the treatment results of MALT lymphomas.
引用
- Yen MT, Bilyk JR, Wladis EJ, et al. Treatments for Ocular Adnexal Lymphoma: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017. PMID: 28712656. doi:10.1016/j.ophtha.2017.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。